Histoplasmosis Treatment Market Report 2026

Histoplasmosis Treatment Market Overview

• Histoplasmosis Treatment market size has reached to $5.5 billion in 2025 • Expected to grow to $8.48 billion in 2030 at a compound annual growth rate (CAGR) of 9.3% • Growth Driver: Rising Incidence Of Chronic Diseases Fuels Expansion In The Histoplasmosis Treatment Market • North America was the largest region in 2025.

What Is Covered Under Histoplasmosis Treatment Market?

Histoplasmosis treatment refers to the medical interventions and therapies used to manage and eliminate the fungal infection caused by the Histoplasma capsulatum fungus. This fungus occurs in dirt, especially near areas where vast quantities of bird or bat droppings accumulate. The specific treatment approach may vary based on the severity of the infection, the patient's overall health and the presence of any underlying medical conditions. The main drug types of histoplasmosis treatment are amphotericin B, itraconazole, ketoconazole and others. Amphotericin B refers to a potent antifungal medication used to treat serious and potentially life-threatening fungal infections. The various modes of administration include injectable, oral, others applied for different patient types such as pediatric and adult. These are used by various end-user such as hospital pharmacies, private clinics, drug stores, retail pharmacies, e-commerce and others.

What Is The Histoplasmosis Treatment Market Growth Forecast?

The histoplasmosis treatment market size is expected to see strong growth in the next few years. It will grow to $8.48 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to increasing demand for advanced antifungal formulations, rising focus on immunocompromised patient care, expansion of oral antifungal therapies, growing investments in infectious disease research, increasing adoption of guideline-based treatment protocols. Major trends in the forecast period include increasing use of targeted antifungal therapies, rising adoption of early diagnostic treatment protocols, growing focus on severe fungal infection management, expansion of hospital-based antifungal care, enhanced emphasis on patient-specific treatment approaches.

Global Histoplasmosis Treatment Market Segmentation

1) By Drug Type: Amphotericin B, Itraconazole, Other Drug Types 2) By Mode of Administration: Injectable, Oral, Other Modes of Administration 3) By Patient Type: Pediatric, Adult 4) By End-User: Hospital Pharmacies, Private Clinics, Drug Stores, Retail Pharmacies, Other End-Users Subsegments: 1) By Amphotericin B: Liposomal Amphotericin B, Conventional Amphotericin B 2) By Itraconazole: Capsule Form, Oral Solution 3) By Other Drug Types: Posaconazole, Voriconazole

What Are The Drivers Of The Histoplasmosis Treatment Market?

The rising incidence of chronic diseases is expected to propel the growth of the histoplasmosis treatment market going forward. Chronic disease is a form of illness that lasts three months or more and can deteriorate with time. Histoplasmosis treatment improves respiratory health, reduces inflammation, enhances immune system function and improves patients' quality of life suffering from chronic diseases. For instance, in April 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency, in 2023, approximately 194 million U.S. adults, or 76.4%, reported having at least one chronic condition. The prevalence was 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Therefore, the rising incidence of chronic diseases is driving the growth of the histoplasmosis treatment industry. The increasing prevalence of human immunodeficiency virus (HIV) is expected to propel the growth of the histoplasmosis treatment market going forward. Human immunodeficiency virus (HIV) refers to a virus that attacks the immune system, specifically targeting CD4 cells (T cells), weakening the body's ability to fight off infections and diseases. Histoplasmosis treatment is crucial for AIDS patients to control the fungal infection, prevent disseminated disease, and reduce mortality by using antifungal medications like itraconazole or amphotericin B. For instance, in August 2024, according to the Minority HIV/AIDS Fund (MHAF), an US-based government agency, an estimated in 2023, approximately 39.9 million individuals worldwide were living with HIV, consisting of 38.6 million adults and 1.4 million children, compared to previous years. Therefore, the increasing prevalence of human immunodeficiency virus (HIV) is driving the growth of histoplasmosis treatment industry.

Key Players In The Global Histoplasmosis Treatment Market

Major companies operating in the histoplasmosis treatment market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A, Bristol Myers Squibb, AstraZeneca Plc, Abbott laboratories, GSK Plc, Eli Lilly and Company, Gilead Sciences, Teva Pharmaceutical Industries Ltd., Astellas pharma US Inc., Mylan N.V., Biogen Inc., Bausch Health Companies Inc., Mitsubishi Tanabe Pharma Corporation, AB Science, Ionis Pharmaceuticals Inc., Advanz Pharma Corp., Leadiant Biosciences, IMMY, Sigma Tau Pharmaceuticals Inc.

What Are Latest Mergers And Acquisitions In The Histoplasmosis Treatment Market?

In March 2024, Sandoz Group AG, a Switzerland-based pharmaceutical company, acquired CIMERLI business from Coherus for an undisclosed amount. The acquisition aims to strengthen Sandoz's ophthalmic portfolio with CIMERLI, positioning the company as a leader in the US biosimilar market and expanding access to affordable treatments for vision impairment. Coherus BioSciences Inc. is a US-based biotech company that specializes in providing treatment for histoplasmosis.

Regional Outlook

North America was the largest region in the histoplasmosis treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Histoplasmosis Treatment Market?

The histoplasmosis treatment consists of sales of antifungal medications and posaconazole. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Histoplasmosis Treatment Market Report 2026?

The histoplasmosis treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the histoplasmosis treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.